BCL2 and breast cancer: For example, MIR-124A is correlated with breast cancer growth and aggressiveness (86), whilst MIR-34B, which has tumor-suppressive effects through the inhibition of BCL-2 (87), is associated to renal cell cancer risk (88) and silenced in hepatocellular carcinoma (89).